Emory/Georgia TB Research Advancement Center (TRAC)

埃默里/佐治亚州结核病研究促进中心 (TRAC)

• 批准号: 10596164
• 负责人: Neel Rajnikant Gandhi
• 金额: $ 97.23万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-03-23 至 2027-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10596164
• 关键词: Acceleration; Administrator; Advanced Development; Animal Model; Basic Science; Bioinformatics; Cause of Death; Centers for Disease Control and Prevention (U.S.); Cessation of life; Clinical; Clinical Research; Clinical Sciences; Collaborations; Communicable Diseases; Communication; Community Health; Country; County; Data; Development; Diabetes Mellitus; Diagnosis; Disease; Drug Kinetics; Drug resistance; Ensure; Epidemiology; Evaluation; Fostering; Foundations; Funding; Goals; Grant; HIV; Health; Human; Immune; Incidence; Individual; Institution; Interdisciplinary Study; International; Investments; Knowledge; Laboratories; Leadership; Mentors; Mentorship; Mission; Morehouse School of Medicine; Mycobacterium tuberculosis; National Institute of Allergy and Infectious Disease; Pathogenesis; Policies; Population Sciences; Prevention; Principal Investigator; Public Health; Research; Research Personnel; Research Project Grants; Resources; Science; Specimen; Strategic Planning; Systems Biology; Technology; Training; Translational Research; Tuberculosis; Universities; Vaccines; Virulence; Vision; Work; World Health Organization; biobank; comorbidity; data sharing; epidemiology study; human population study; improved; innovation; multidisciplinary; next generation; nonhuman primate; organizational structure; pandemic disease; programs; response; success; tool; transmission process; tuberculosis diagnostics; tuberculosis immunity; tuberculosis treatment

Tuberculosis (TB) remains the leading infectious cause of death worldwide. Although the World Health Organization (WHO) End TB Strategy sets ambitious goals to reduce TB incidence by 90% by 2035, we are not on track to achieve them. We will need to “accelerate basic, translational, and clinical research to improve understanding of TB and expedite the development of innovative new tools and strategies to improve diagnosis, prevention, and treatment to end the TB pandemic,” as stated in the NIAID Strategic Plan for TB. We propose the Emory/Georgia TB Research Advancement Center (TRAC) to catalyze and elevate multidisciplinary basic, translational and clinical TB research at Emory University and partner institutions: University of Georgia, Georgia Institute of Technology, Georgia State University, and Morehouse School of Medicine. The Emory/Georgia TRAC builds upon the strong foundation established by the Emory TB Center, created in 2020 in response to the growing number of investigators engaged in TB research. Across all the Emory/Georgia TRAC institutions, there is a critical mass of 72 investigators engaged in TB research, and TB PI/MPIs have received a total of over $104 million in TB research funding since 2010. Expertise in our TRAC represents the full spectrum of TB science: TB transmission and epidemiology, human immunity to TB, pathogenesis of TB using animal models (including non-human primates [NHP]), TB diagnostics, vaccines and host-directed therapies, pharmacokinetics, drug-resistance and TB comorbidities (HIV, diabetes). The Emory/Georgia TRAC will create added value by leveraging the scientific strengths at TRAC institutions to catalyze and expand multidisciplinary TB research. The TRAC will provide financial, logistical, and intellectual resources, pilot grants, and mentoring via a Developmental Core, Clinical & Population Science Core, Basic & Translational Science Core, and Bioinformatics & Integrated Systems Biology Core. These Cores will provide training and access to human study populations in high burden countries and the US, resources for BSL3 laboratory-based Mtb and animal model research, including NHP, and opportunities to utilize cutting-edge technologies and systems biology that can be leveraged for new multidisciplinary and translational TB studies. Further, the TRAC will provide mentorship and support for early- stage and non-TB investigators and create shared data and specimen biorepositories that will be a resource for new study ideas and preliminary data. The Emory/Georgia TRAC, through its Core activities and resources, will achieve these overarching aims: Aim 1: To catalyze and expand collaborative multidisciplinary TB research among established basic, clinical and translational TB investigators and collaborators in the U.S. and internationally; Aim 2: To capitalize on the strengths of the Emory/Georgia TRAC universities to grow and diversify TB research in new directions; and Aim 3: To identify, train and mentor the next generation of TB researchers and scientific leaders.

结核病(TB)仍然是世界范围内主要的死亡传染病。尽管世界卫生组织 世界卫生组织(WHO)结束结核病战略制定了雄心勃勃的目标，到2035年将结核病发病率降低90%，我们 没有走上实现这些目标的轨道。我们将需要“加速基础研究、转化研究和临床研究，以提高 了解结核病并加快开发创新的新工具和战略，以改善 诊断、预防和治疗，以结束结核病大流行“，如NIAID结核病战略计划所述。 我们建议埃默里/佐治亚州结核病研究促进中心(TRAC)催化和提升 埃默里大学及其合作机构的多学科基础、转化性和临床结核病研究： 佐治亚大学、佐治亚理工学院、佐治亚州立大学和莫尔豪斯学院 医学。埃默里/佐治亚州TRAC建立在埃默里结核病中心建立的坚实基础上， 创建于2020年，以应对越来越多的从事结核病研究的调查人员。在所有的 埃默里/佐治亚州TRAC机构，有72名研究人员从事结核病研究，结核病 自2010年以来，PI/MPIs总共收到了超过1.04亿美元的结核病研究资金。我们的TRAC中的专业知识 代表了结核病科学的全部领域：结核病传播和流行病学、人类对结核病的免疫力、 使用动物模型(包括非人类灵长类动物[NHP])、结核病诊断、疫苗和 宿主导向疗法、药代动力学、抗药性和结核病合并症(艾滋病毒、糖尿病)。 埃默里/佐治亚州TRAC将利用TRAC的科学优势创造附加值 促进和扩大多学科结核病研究的机构。TRAC将提供财政、后勤、 和智力资源、试点资助和通过发展核心、临床和人口进行的指导 科学核心、基础与翻译科学核心、生物信息学与集成系统生物学 核心。这些核心将为高负担国家和地区的人类研究人口提供培训和机会。 美国，基于BSL3实验室的Mtb和动物模型研究的资源，包括NHP，以及 利用尖端技术和系统生物学的机会，可用于新的 多学科和转化性结核病研究。此外，核心目标咨询委员会将为早期- 阶段性和非结核病调查人员，并创建共享数据和标本生物库，作为资源 寻找新的研究思路和初步数据。埃默里/格鲁吉亚核心目标咨询委员会通过其核心活动和资源， 将实现这些首要目标：目标1：促进和扩大协作的多学科结核病 在美国和美国现有的基础、临床和转化型结核病研究人员和合作者中进行的研究 国际；目标2：利用埃默里/格鲁吉亚TRAC大学的优势，发展和 在新的方向上使结核病研究多样化；目标3：识别、培训和指导下一代结核病 研究人员和科学领袖。